Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
O6-benzylguanine and carmustine in multiple myeloma
NCT00004072Phase 2Completed
- Sponsor
- Case Comprehensive Cancer Center
- Start
- Sep 1999
- Primary completion
- Aug 2004
- Modality
- Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of 6-benzylguanine in multiple myeloma (MM), sponsored by Case Comprehensive Cancer Center. Primary endpoints: Overall Response Rate and Effect on bone marrow myeloma cells. Started Sep 1999; status: completed.
02
Drugs
6-benzylguanine
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00004072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00004072.